2020
DOI: 10.1111/bjd.19627
|View full text |Cite
|
Sign up to set email alerts
|

An additional drug repurposing study for hidradenitis suppurativa/acne inversa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 8 publications
0
4
0
2
Order By: Relevance
“…Among the 386 HS-associated DEGs, 105 druggable genes were recognized. With the 11 additional druggable genes described by Zouboulis et al [12], namely ABAT, ADRA1A, CYP3A4, GRM4, HRH1, OPRD1, OPRM, PRKAB1, PTGS1, PTGS2 and SLC6A4, the overall detected druggable genes in HS are 116.…”
Section: Enrichment Analysis Of Hs Druggable Genesmentioning
confidence: 93%
“…Among the 386 HS-associated DEGs, 105 druggable genes were recognized. With the 11 additional druggable genes described by Zouboulis et al [12], namely ABAT, ADRA1A, CYP3A4, GRM4, HRH1, OPRD1, OPRM, PRKAB1, PTGS1, PTGS2 and SLC6A4, the overall detected druggable genes in HS are 116.…”
Section: Enrichment Analysis Of Hs Druggable Genesmentioning
confidence: 93%
“…On the other hand, the urgent need for robust information from preclinical research is undersigned by the last – due to diverse reasons – unsatisfactory efforts to provide therapeutic efficacy in clinical HS studies, such the ones using complement (C)5a receptor and interleukin (IL)‐23 as treatment targets. Competent models for preclinical research have already been published, namely three‐dimensional skin culture systems, 3,4 differential gene and protein expression studies 5,6 and repurposing analyses 7,8 . Indeed, conducting inclusive, long‐term, controlled multi‐centre clinical trials investigating different biological agents or drugs with ancillary analyses of transcriptomes based on next‐generation sequence studies will leap forward the HS patient journey.…”
Section: Introductionmentioning
confidence: 99%
“…Although the inflammatory signature of circulating proteins may not completely reflect the lesional skin of patients with HS or an intrinsic defect of HS epithelial cells leading to inflammation, 55–57 the identification of responder/nonresponder at baseline and post‐treatment responses suggests the feasibility of this approach from a biomarker standpoint. These identified molecular mediators that could be potential targets for HS therapies 58,59 . While this study had a small sample size and was not validated in a large study cohort to verify the prediction model, several findings are consistent with TNF biology and HS pathogenesis 7,21,22 .…”
Section: Discussionmentioning
confidence: 75%
“…These identified molecular mediators that could be potential targets for HS therapies. 58,59 While this study had a small sample size and was not validated in a large study cohort to verify the prediction model, several findings are consistent with TNF biology and HS pathogenesis. 7,21,22 Additional confirmation of these observations will be tested in the recently completed SHARPS [Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa Peri-Surgically] clinical trial (M11-574, ClinicalTrials.gov Identifier: NCT02808975).…”
Section: Discussionmentioning
confidence: 86%